Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

ClinicalTrials.gov ID: NCT00082433

Public ClinicalTrials.gov record NCT00082433. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Study of Novel Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With an Anthracycline and a Taxane

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer. Patients should have previously received an anthracycline and a taxane. The safety of this treatment will also be studied.

Study identification

NCT ID
NCT00082433
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
R-Pharm
Industry
Enrollment
1,221 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2003
Primary completion
Feb 29, 2008
Completion
Feb 29, 2008
Last update posted
Nov 1, 2020

2003 – 2008

United States locations

U.S. sites
34
U.S. states
23
U.S. cities
34
Facility City State ZIP Site status
Local Institution Tucson Arizona
Local Institution Beverly Hills California
Local Institution Corona California
Local Institution Hartford Connecticut
Local Institution Plantation Florida
Local Institution Boise Idaho
Local Institution Evanston Illinois
Local Institution Iowa City Iowa
Local Institution Louisville Kentucky
Local Institution Baton Rouge Louisiana
Local Institution Bethesda Maryland
Local Institution Boston Massachusetts
Local Institution Jackson Mississippi
Local Institution Columbia Missouri
Local Institution Voorhees Township New Jersey
Local Institution Albuquerque New Mexico
Local Institution Latham New York
Local Institution Mineola New York
Local Institution New York New York
Local Institution The Bronx New York
Local Institution Durham North Carolina
Local Institution Goldsboro North Carolina
Local Institution Hickory North Carolina
Local Institution Kinston North Carolina
Local Institution Canton Ohio
Local Institution Columbus Ohio
Local Institution Langhorne Pennsylvania
Local Institution Knoxville Tennessee
Local Institution Memphis Tennessee
Local Institution Dallas Texas
Local Institution Charlottesville Virginia
Local Institution Norfolk Virginia
Local Institution Richmond Virginia
Local Institution Marshfield Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 152 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00082433, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 1, 2020 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00082433 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →